8-K: Quantum-Si Reports Q4/FY25 Results, Sets Proteus Price

Quantum-Si Incorporated announced its fourth quarter and full year 2025 financial results, revealing a list price for its Proteus platform and providing 2026 financial guidance.

Summary

• Fourth quarter 2025 revenue was $0.5 million, with full year 2025 revenue reaching $2.4 million.
• Net loss for Q4 2025 was $17.6 million, an improvement from $33.1 million in Q4 2024.
• Full year 2025 net loss was $101.3 million, slightly higher than $101.0 million in FY 2024.
• Adjusted EBITDA for Q4 2025 was negative $17.0 million, an improvement from negative $25.1 million in Q4 2024.
• Adjusted EBITDA for full year 2025 was negative $80.7 million, an improvement from negative $92.8 million in FY 2024.
• Cash and cash equivalents and investments in marketable securities totaled $215.8 million as of December 31, 2025.
• The list price for the Proteus platform was announced at $425,000.
• 2026 financial guidance includes approximately $1.0 million in revenue, adjusted total operating expenses of $98.0 million or less, and total cash usage of $93.0 million or less.
• The Proteus development program remains on track for a year-end 2026 launch.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While cost discipline and Proteus development are positive, the significant reduction in 2026 revenue guidance indicates a challenging transition period for the company's commercial efforts.

Positives

• Net loss for Q4 2025 significantly improved to $17.6 million compared to $33.1 million in the same period of the prior year.
• Adjusted EBITDA for Q4 2025 improved to negative $17.0 million from negative $25.1 million in the prior year.
• Adjusted EBITDA for the full year 2025 improved to negative $80.7 million from negative $92.8 million in the prior year, reflecting continued cost discipline.
• Cash and cash equivalents and investments of $215.8 million as of December 31, 2025, are projected to provide sufficient runway into the second quarter of 2028.
• The Proteus development program is on track for its anticipated year-end 2026 launch.
• The early release of the Proteus list price ($425,000) allows commercial teams to more effectively work with customers on capital budgeting cycles.
• Demonstrated sequencing on the Proteus prototype system exceeded current technology across all key performance metrics.

Negatives

• Full year 2025 revenue decreased to $2.4 million from $3.058 million in 2024.
• Full year 2025 net loss slightly increased to $101.3 million from $101.0 million in 2024.
• 2026 revenue guidance of approximately $1.0 million is significantly lower than 2025 revenue, impacted by strategic choices like upgrade credits and customer delays.
• Gross margin is expected to be variable in the near term as the company progresses through initial commercialization stages.
• Total operating expenses for the full year 2025 increased to $117.3 million from $110.2 million in 2024.
• Included one-time charges of $18.7 million associated with legacy litigation matters in total operating expenses and net loss for 2025.

Risks

• The inability to maintain the listing of Class A common stock on The Nasdaq Stock Market.
• The ability to grow and manage growth profitably and retain key employees.
• Ongoing leadership transitions within the company.
• Changes in applicable laws or regulations.
• The ability to raise financing in the future.
• The success, cost, and timing of product development and commercialization activities, including the use and benefit of artificial intelligence.
• The commercialization and adoption of existing products and the success of any future products.
• The potential attributes and benefits of commercialized Platinum protein sequencing instruments and kits and other future products.
• The ability to obtain and maintain regulatory approval for products, and any related restrictions and limitations.
• The ability to identify, in-license, or acquire additional technology.
• The ability to maintain existing lease, license, manufacture, and supply agreements.
• The ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources.
• The size and growth potential of the markets for products and services, and the ability to serve those markets once commercialized.
• Estimates regarding future expenses, future revenue, capital requirements, and needs for additional financing.
• The company's financial performance.

Future Outlook

Quantum-Si anticipates 2026 to be a transition year with tempered near-term revenue of approximately $1.0 million, due to strategic actions like embedding upgrade credits into Platinum Pro units and customers delaying purchases in anticipation of the Proteus platform. The company expects adjusted total operating expenses to be $98.0 million or less and total cash usage to be $93.0 million or less, while prioritizing investments for the Proteus platform's year-end 2026 commercial launch. Cash and investments of $215.8 million are projected to provide sufficient runway into the second quarter of 2028.

Management Comments

• "2025 was a year of significant progress as we continued to advance our technology through multiple new kit launches, expanding the installed base and consumable utilization of our first-generation Platinum Pro system, and delivered on our key strategic goal of demonstrating sequencing on our Proteus prototype system that exceeded our current technology across all key performance metrics." Jeff Hawkins, President and Chief Executive Officer.
• "Since our Investor & Analyst Day in November 2025, engagement from both existing and prospective customers around Proteus has developed nicely. Given the level of customer, prospective customer, and channel partner interest, we elected to release our Proteus list price a quarter earlier than originally planned, allowing our commercial team to more effectively work with customers to incorporate Proteus into their capital budgeting cycles." Jeff Hawkins, President and Chief Executive Officer.
• "At a list price of $425,000, we believe Proteus is priced to capture the premium value of the platform and expected launch capabilities while also making the platform accessible to a larger number of potential customers than existing technologies." Jeff Hawkins, President and Chief Executive Officer.
• "As we move through 2026, we expect tempered nearterm revenue based upon deliberate strategic choices. These include continuing to offer the placement program we initiated during 2025 and embedding upgrade credits into Platinum Pro units sold during 2026 to provide a clear path to Proteus for customers. While this approach moderates nearterm revenue, we believe it positions Proteus for a stronger launch and supports longterm shareholder value creation." Jeff Hawkins, President and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Quantum-Si's strategic decision to temper near-term revenue in 2026 by offering upgrade credits and placement programs for its Platinum Pro system, while positioning for the Proteus platform launch, reflects a common industry strategy in high-growth, innovative sectors. Companies often prioritize long-term market adoption and platform transitions over immediate revenue recognition when introducing disruptive technologies. The early release of the Proteus list price also indicates a proactive approach to engage with customers and integrate into their capital budgeting cycles, a critical factor in the sales cycle for high-value scientific instruments.

Comparison to Industry Standards

• The Proteus platform's list price of $425,000 positions it as a premium offering in the proteomics instrument market, comparable to high-end mass spectrometry systems from companies like Thermo Fisher Scientific (e.g., Orbitrap series) or Bruker (e.g., timsTOF Pro), which can range from $300,000 to over $1 million depending on configuration and capabilities.
• The reported gross margin of 27% for Q4 2025 and 47% for FY 2025 is lower than established life science tool companies like Illumina or Agilent Technologies, which often report gross margins in the 60-70% range, reflecting Quantum-Si's earlier stage of commercialization and higher initial production costs.
• The significant cash burn and negative EBITDA are typical for early-stage biotechnology companies heavily invested in R&D and commercialization of novel platforms, similar to where companies like Pacific Biosciences or Oxford Nanopore Technologies were in their initial growth phases, prior to achieving broader market penetration and economies of scale.

Legal Proceedings

• One-time charges associated with legacy litigation matters totaling $18.7 million were reserved or settled during the year ended December 31, 2025.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if Proteus launch is successful, but near-term revenue contraction and continued losses may impact share price.
• Customers: Platinum Pro customers benefit from upgrade credits and a clear path to the Proteus platform; prospective customers can plan capital budgets with the early release of Proteus pricing.
• Employees: Continued focus on Proteus execution and launch readiness, with disciplined operating expense management, implies resource allocation towards key strategic areas.

Next Steps

• Continue development and support of the commercial launch of the Proteus platform.
• Commercial launch of the Proteus platform with anticipated capabilities by the end of 2026.
• Manage operating expenses with discipline, prioritizing investments directly tied to Proteus execution and launch readiness.
• Modest inventory build and commercial readiness activities ahead of the anticipated Proteus launch.
• Host a conference call on March 3, 2026, to discuss the fourth quarter and full year 2025 financial results.

Key Dates

Recommendation

While Quantum-Si shows progress in cost management and Proteus development, the substantially lower 2026 revenue guidance indicates a challenging transition year. The long-term potential of Proteus is promising, but the near-term commercial headwinds and continued losses suggest a "hold" position until there is clearer evidence of Proteus market adoption and revenue growth.

Keywords

Proteomics, Single-molecule detection, Protein analysis, Proteus platform, Platinum Pro, Financial results, SEC filing, QSI, Quantum-Si, Biotechnology, Life sciences, Diagnostics, Research and development, Financial guidance